A year after US approval, CAR-Ts from Novartis, Gilead get European green light
Negotiations with country-level reimbursement authorities will follow. The UK's NICE turned down Gilead's Yescarta Tuesday.
Sutro raises $85.4 million in Series E round to advance blood cancer, solid tumor drugs
Latest round of venture capital funding brings total amount raised to $175 million since 2003.
Using Informed Awareness to Transform Care Coordination and Improve the Clinical and Patient Experience
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
Karyopharm seeks FDA approval for drug in highly refractory blood cancer
Drugmaker applies for selinexor in penta-refractory multiple myeloma, in which bluebird's bb2121 has also shown efficacy.
FDA approves Agios Pharmaceuticals’ Tibsovo for acute myeloid leukemia
The approval is the latest of several drugs approved for the disease, a form of blood cancer, since last year.
CAR-T has a lot of promise, but some big challenges remain, experts at BIO, ASCO say
Many issues around CAR-T remain to be hashed out, but many experts pointed to infrastructure and clinics' capabilities as crucial.
Accent Therapeutics launches with $40 million Series A round
Company will pursue RNA-modifying protein targets to discover and develop new treatments in oncology.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Anatomy of two biotech deals worth $20B
Analysts had forecast a blockbuster year for life science M&As, with the tax reforms taking effect and Big Pharma scrambling for late-stage assets. Less than one month in, the predictions seem to be coming true.
GE Ventures spinoff wants to take the sting out of blood tests
GE Ventures has been incubating Drawbridge Health for two years. With its pain-free blood draw device, the business seeks to increase patient compliance and simplify the diagnostic workflow.
Symptom tracker app for patients with rare bone marrow diseases aims to improve outcomes
Update below About 18,250 people are diagnosed with bone marrow failure each year. A non profit foundation and a behavior change app producer 2morrow have collaborated on an app to help patients record their reaction to therapies to improve outcomes. The Aplastic Anemia & MDS International Foundation contributed the content for the mobile device app […]
Diagnostic to assess clotting disorders in surgery raises new capital
A medical device company has raised nearly $1.3 million to advance a diagnostic to detect life-threatening bleeding and blood clots, according to a Form D filing with the U.S. Securities and Exchange Commission. HemoSonics‘ Point of Care Analyzer evaluates the systems that manage clotting: platelets, coagulation factors, fibrinogen and fibrinolytic proteins. The device is being […]
BioLabs Pegasus Park Cultivates Life Science Ecosystem
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
Therapeutic could improve hemophilia B patients’ quality of life with reduced jabs
A drug developer has initiated enrollment for a phase 3 trial for a hemophilia therapeutic that could reduce the frequency that people with the rare blood disorder need to take medication. The move is part of a larger trend of biotechnology companies in this area that focus on reducing injections from daily to weekly CSL […]
Celgene submits NDA for multiple myeloma, forges personalized medicine collaboration
Celgene (NASDAQ:CELG) has submitted a new drug application to the U.S. Food and Drug Administration for pomalidomide, a drug designed for multiple myeloma that does not respond to therapies. Since the drug is for an unmet need, the company stands to get a priority review. It is also planning to submit a marketing application submission […]
Oral anemia drug meets primary endpoints in phase 2 trial
A once-daily oral anemia drug from Akebia Therapeutics met its primary endpoint in a phase 2a trial of chronic kidney disease patients. The successful 42-day trial of the drug, now called AKB-6548, sets the stage for a longer 2b trial that would follow patients for six months, said Bill Daly, Akebia’s senior vice president of […]
Hemophilia therapeutic from CSL Behring gets orphan drug status
A drug therapy for hemophilia patients developed by CSL Behring has been given orphan drug status by U.S. regulators. The hemophilia therapeutic from CSL Behring, a plasma protein therapeutics producer in King of Prussia, Pennsylvania, links recombinant fusion protein coagulation factor VIIa with albumin. The treatment is designed to help hemophilia A and hemophilia B […]
Celgene invests $15 million for closer collaboration with cancer drug co.
Celgene (NYSE:CELG) has made a $15 million strategic investment in a cancer drug developer, which gives it a seat on the company’s board and opens up collaboration opportunities down the road. Acetylon Pharmaceuticals uses histone deacetylase or HDAC inhibitors to develop small molecule cancer treatments as well as treatments for autoimmune and other diseases. The lead […]